Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 6, 2007, Pages 754-759

  Tingstedt, Bobby ^a   Johansson, Patrik ^a   Andersson, Bodil ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CRP; Pancreatic ductal adenocarcinoma; Prognostic factor; Survival

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOSCOPIC SURGERY; FEMALE; GASTROENTEROSTOMY; HEPATOJEJUNOSTOMY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34248579658     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601058452     Document Type: Article

References (31)

1. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Luttges J, Klöppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the date of the Finnish Cancer Registry. Gut 2005;54:385-7.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
3. Cancer Incidence in Sweden. The Swedish Cancer Registry, Health and diseases 2004:10, National Board of Health and Welfare 2004. p 66. Table 4.
4. Hjelmgren J, Ceberg J, Persson U, Alvegard TA. The cost of treating pancreatic cancer: a cohort study based on patients' records from four hospitals in Sweden. Acta Oncol 2003;42:218-26.
5. De Braud F, Cascinu S, Gatta G. Cancer of pancreas. Crit Rev Oncol Hematol 2004;50:147-55.
6. Treatment guidelines 2003: pancreatic cancer and periampullary cancer. Stockholm - Gotland: Centre for Oncology; 2003.
7. Birk D, Beger HG. Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer. Curr Gastroenterol Rep 2001;3:129-35.
8. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Kink K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in respectable pancreatic cancer: a randomised trial. Lancet 2001;358:1576-85.
9. Li D, Xie K, Wollf R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
10. Kuhlmann KFD, de Castro SMM, Wesseling JG, ten Kate GJA, Offerhaus GJA, Busch ORC, et al. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-58.
11. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296-301.
12. Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 2005;241:295-9.
13. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. European Study Group for Pancreatic Cancer. A randomised trial of chemo radiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
14. Engelken FJF, Bettschart V, Rahman MQ, Park RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. EJSO 2003;29:368-73.
15. Sohn TA, Lillemoe KD. Surgical palliation of pancreatic cancer. Adv Surg 2000;34:249-71.
16. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KCH. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53-8.
17. Falconer JS, Fearon KCH, Ross JA, Elton R, Wigmore SJ, Garden OJ, et al. Acute-phase protein response and survival duration of patient with pancreatic cancer. Cancer 1995;75:2077-82.
18. Ganrot PO, Grubb A, Stenflo J. Laurell's clinical chemistry in practical medicine, 7th ed. Lund: Studentlitteratur; 1997. pp 116-9.
19. Treatment guidelines for pancreatic cancer. Centre for oncology, South region Sweden 1999.
20. Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075-84.
21. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-3.
22. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005;8:265-9.
23. Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999;23:584-8.
24. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990;12:1176-81.
25. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999;35:106-10.
26. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. Clin Pathol 2004;57:630-6.
27. Merata K, Siadaty MS, Andea A, Sarkar F, Ben-Josef E, Mohammad R, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-52.
28. Grover JK, Yadav S, Vats V, Joshi YK. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 2003;18:279-91.
29. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004;3:1421-6.
30. Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Inhibition of the phosphatidylinositol 3′-kinase signalling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003;7:354-63.
31. Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185-8.